Indication:
Osmigen tablets, containing 80 mg of Osimertinib, are prescribed for treating advanced or metastatic non-small cell lung cancer (NSCLC) with the presence of epidermal growth factor receptor (EGFR) T790M mutation.

Pharmacology:
Osimertinib, the primary component in Osmigen tablets, acts as a third-generation inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR TKI). It selectively and irreversibly inhibits both EGFR-sensitizing and T790M resistance mutations, effectively halting tumor growth and proliferation in EGFR-mutated NSCLC.

Dosage and Administration:
The typical dosage of Osmigen tablets is 80 mg taken orally once daily, with or without food. It’s important to swallow the tablets whole with a glass of water. Adjustments or interruptions in dosage may be necessary based on individual patient response and tolerance.

Interaction:
Osimertinib may interact with various medications, notably strong CYP3A inhibitors and inducers, potentially impacting its metabolism and effectiveness. Patients should disclose all medications, supplements, and herbal products to their healthcare provider to avoid potential interactions.

Side Effects:
Common side effects of Osmigen tablets may include diarrhea, rash, dry skin, nail changes, and fatigue. More severe side effects like interstitial lung disease, QT prolongation, and cardiomyopathy are possible. Patients should promptly report any severe or persistent side effects to their healthcare provider.

Precautions and Warnings:
Patients undergoing treatment with Osmigen should undergo regular monitoring for potential adverse reactions, particularly lung function tests and cardiac assessments. Use of Osimertinib during pregnancy can lead to fetal harm, necessitating contraception for both males and females during treatment and for a certain period afterward. Breastfeeding is not recommended while taking Osmigen.

Overdose Effects:
In instances of Osmigen overdose, patients may experience intensified adverse effects such as diarrhea, rash, and QT prolongation. Management typically involves supportive care and monitoring for complications. Immediate medical attention is advised if overdose is suspected.